Evidence map›Paper›PMID 30365535›Full record

ArticlePLoS pathogens2018

The Citrobacter rodentium type III secretion system effector EspO affects mucosal damage repair and antimicrobial responses.

Cedric N Berger, Valerie F Crepin, Theodoros I Roumeliotis, James C Wright, Nicolas Serafini, Meirav Pevsner-Fischer, Lu Yu, Eran Elinav, James P Di Santo, Jyoti S Choudhary and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Attaching and effacing pathogens modulate host mitochondrial structure and function.International review of cell and molecular biology · 2023
    Review
  10. Review
  11. Simulated Colonic Fluid Replicates theInfection and immunity · 2022
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Cedric N BergerMRC Centre for Molecular Bacteriology and Infection, Department of Life Sciences, Imperial College London, London, United Kingdom.ORCID 0000-0002-1316-5985
Valerie F CrepinMRC Centre for Molecular Bacteriology and Infection, Department of Life Sciences, Imperial College London, London, United Kingdom.
Theodoros I RoumeliotisDivision of Cancer Biology, The Institute of Cancer Research London, London, United Kingdom.ORCID 0000-0002-3354-5643
James C WrightDivision of Cancer Biology, The Institute of Cancer Research London, London, United Kingdom.ORCID 0000-0001-6950-4328
Nicolas SerafiniInnate Immunity Unit, Institut Pasteur, Paris, France.
Meirav Pevsner-FischerDepartment of Immunology, the Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0001-7773-9100
Lu YuDivision of Cancer Biology, The Institute of Cancer Research London, London, United Kingdom.
Eran ElinavDepartment of Immunology, the Weizmann Institute of Science, Rehovot, Israel.
James P Di SantoInnate Immunity Unit, Institut Pasteur, Paris, France.ORCID 0000-0002-7146-1862
Jyoti S ChoudharyDivision of Cancer Biology, The Institute of Cancer Research London, London, United Kingdom.ORCID 0000-0003-0881-5477
Gad FrankelMRC Centre for Molecular Bacteriology and Infection, Department of Life Sciences, Imperial College London, London, United Kingdom.ORCID 0000-0002-0046-1363
Institute of Cancer Research · GBImperial College London · GBInserm · FRWeizmann Institute of Science · IL

Funding

Medical Research Council MR/K019007/1Medical Research Council MR/P028225/1Wellcome TrustWellcome Trust 107057/Z/15/ZWellcome Trust 695467Wellcome Trust WT098051
6 · The paper itself

Abstract

Infection with Citrobacter rodentium triggers robust tissue damage repair responses, manifested by secretion of IL-22, in the absence of which mice succumbed to the infection. Of the main hallmarks of C. rodentium infection are colonic crypt hyperplasia (CCH) and dysbiosis. In order to colonize the host and compete with the gut microbiota, C. rodentium employs a type III secretion system (T3SS) that injects effectors into colonic intestinal epithelial cells (IECs). Once injected, the effectors subvert processes involved in innate immune responses, cellular metabolism and oxygenation of the mucosa. Importantly, the identity of the effector/s triggering the tissue repair response is/are unknown. Here we report that the effector EspO ,an orthologue of OspE found in Shigella spp, affects proliferation of IECs 8 and 14 days post C. rodentium infection as well as secretion of IL-22 from colonic explants. While we observed no differences in the recruitment of group 3 innate lymphoid cells (ILC3s) and T cells, which are the main sources of IL-22 at the early and late stages of C. rodentium infection respectively, infection with ΔespO was characterized by diminished recruitment of sub-mucosal neutrophils, which coincided with lower abundance of Mmp9 and chemokines (e.g. S100a8/9) in IECs. Moreover, mice infected with ΔespO triggered significantly lesser nutritional immunity (e.g. calprotectin, Lcn2) and expression of antimicrobial peptides (Reg3β, Reg3γ) compared to mice infected with WT C. rodentium. This overlapped with a decrease in STAT3 phosphorylation in IECs. Importantly, while the reduced CCH and abundance of antimicrobial proteins during ΔespO infection did not affect C. rodentium colonization or the composition of commensal Proteobacteria, they had a subtle consequence on Firmicutes subpopulations. EspO is the first bacterial virulence factor that affects neutrophil recruitment and secretion of IL-22, as well as expression of antimicrobial and nutritional immunity proteins in IECs.

Indexed as

AnimalsAntimicrobial Cationic PeptidesCitrobacter rodentiumEnterobacteriaceae InfectionsFemaleImmunity, InnateIntestinal MucosaMiceMice, Inbred C57BLType III Secretion SystemsAntimicrobial Cationic PeptidesType III Secretion Systems

Identifiers

PMID30365535
PMCPMC6221368
OpenAlexW2898102921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.